Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy

Gut

Volumn 42, Issue 6, 1998, Pages 861-867

  Avallone, R ^a   Zeneroli, M L ^a   Venturini, I ^a   Corsi, L ^a   Schreier, P ^b   Kleinschnitz, M ^b   Ferrarese, C ^c   Farina, F ^a   Baraldi, C ^a   Pecora, N ^c   Frigo, M ^c   Baraldi, M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Benzodiazepine consumers; Diazepam binding inhibitor; Endogenous benzodiazepines; Liver cirrhosis; Overt hepatic encephalopathy

Indexed keywords

DIAZEPAM; NORDAZEPAM;

ADULT; AGED; ARTICLE; DOSE LIVER FUNCTION RELATION; DRUG ACCUMULATION; DRUG LIVER LEVEL; DRUG RECEPTOR BINDING; FEMALE; HEPATIC ENCEPHALOPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CIRRHOSIS; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 15644365450     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.6.861     Document Type: Article

References (35)

1. Zeneroli ML. Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure. J Hepatol 1985;1:301-12.
2. Jones EA, Skolnick P, Gammal H, et al. The gamma-aminobutyric acid-A (GABA-A) receptor complex and hepatic encephalopathy. Some recent advances. Ann Intern Med 1989;110:532-46.
3. Baraldi M. Supersensitivity of GABA-A receptors in hepatic encephalopathy. Neurochem Res 1990;15:153-60.
4. Baraldi M, Zeneroli ML, Ventura E, et al. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by benzodiazepine antagonist. Clin Sci 1984;67:167-75.
5. Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet 1985; 1:1324.
6. Bansky G, Meier PJ, Ziegler WH, et al. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet 1985;1:1324-5.
7. Olasmaa M, Guidotti A, Costa E, et al. Endogenous benzodiazepines in hepatic encephalopathy. Lancet 1989;1:491-2.
8. Basile AS, Gammal SH, Jones EA, et al. GABA-A receptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous benzodiazepine receptor complex ligand. J Neurochem 1989;53:1057-63.
9. Olasmaa M, Rothstein JD, Guidotti A, et al. Endogenous benzodiazepine in human and animal hepatic encephalopathy. J Neurochem 1990;55:2015-23.
10. Mullen KD, Szauter KM, Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990;336:81-3.
11. Baraldi M, Zeneroli ML, Rothstein JD, et al. Increased presence of benzodiazepine-like compounds in a rat model of hepatic encephalopathy. In: Bengtsson F, Jeppson B, eds. Progress in hepatic encephalopathy. Miami: CRC Press, 1991: 155-60.
12. Basile AS, Hughes RD, Harrison PH, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991;325:473-8.
13. Basile AS, Harrison PM, Hughes RD, et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994;19:112-21.
14. Mullen KD, Martin JV, Mendelson WB, et al. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1988;1:457-9.
15. Baraldi M, Pinelli G, Ricci P, et al. Toxins in hepatic encephalopathy: the role of the synergistic effect of ammonia, mercaptans and short chain fatty acids. Arch Toxicol 1984;7(suppl):103-5.
16. 3H]PK11195. Neurosci Lett 1994; 177:35-8.
17. Basile AS, Jones EA. Ammonia and GABAergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997;25:1303-5.
18. Medina JH, Pena C, Levi de Stein M, et al. Benzodiazepine-like molecules as well as other ligands for the brain benzodiazepine receptors, are relatively common constituents of plants. Biochem Biophys Res Commun 1989;165:547-53.
19. Sangameswaran L, De Bias AL. Demonstration of the benzodiazepine-like molecules in the mammalian brain with a monoclonal antibody to benzodiazepines. Proc Natl Acad Sci USA 1985;82:5560-4.
20. De Blas AL, Park D, Friedrich P. Endogenous benzodiazepine-like molecules in human, rat and bovine brains studied with a monoclonal antibody to benzodiazepines. Brain Res 1987;413:275-84.
21. Zeneroli ML, Venturini I, Stefanelli S, et al. Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacol Res 1997;35:557-60.
22. Guidotti A, Forchetti CM, Corda MG, et al. Isolation, characterization and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci USA 1983;80:3531-5.
23. Rothstein JD, Mckhann G, Guarnieri P, et al. Cerebrospinal fluid content of diazepam binding inhibitor (DBI) in chronic hepatic encephalopathy. Ann Neurol 1989;26:57-62.
24. Butterworth RF, Tonon MC, Desy L, et al. Increased brain content of the endogenous benzodiazepine receptor ligand, octadecaneuropeptide (ODN), following portacaval anastomosis in the rat. Peptides 1991;12:119-25.
25. Kennedy J, Parbhoo SP, MacGilivray B, et al. Effect of extracorporeal liver perfusion on the electroencephalogram of patients in coma due to acute liver failure. Q J Med 1973;42:549-61.
26. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
28. Kleinschnitz M, Herderich M, Schreier P. Determination of 1,4-benzodiazepines by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Biomed Appl 1996;676:61-7.
29. Ferrarese C, Apollonio L, Frigo M, et al. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia. Neurology 1990;40:632-5.
30. Ferrarese C, Appollonio I, Frigo M, et al. Distribution of a putative endogenous modulator of the GABAergic system in human brain. Neurology 1989;39:443-5.
31. Kolmer M, Pelto-Huikko M, Alho H. Germ-cell specific transcription of the diazepam binding inhibitor (DBI) gene in testis: evidence for translational control. DNA Cell Biol 1997;16:59-72.
32. Greenblatt DJ, Miller LG, Shader RI. Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med 1990;88:194-236.
33. Branch RA, Morgan MH, James J, et al. Intravenous administration of diazepam in patients with chronic liver disease. Gut 1976;17:975-83.
34. Baktir GA, Fisch HU, Karlaganis G, et al. Mechanism of the excessive sedative response of cirrhotics to benzodiazepine: model experiments with triazolam. Hepatology 1987;7:629-38.
35. Papadopoulos V, Berkovich A, Krueger KE, et al. Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors. Endocrinology 1991;129:1481-7.